Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Executive Summary
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
You may also be interested in...
Remicade: A Study In Translational Looping
The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: